© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
American Headache Society Annual Scientific Meeting
Fremanezumab Yields Monthly Migraine and Headache Reductions in Real-World Setting
June 08, 2021
Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.
No Significant Wearing Off Effect With Galcanezumab for Migraine Prevention
June 08, 2021
A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.
Applying Data on CGRP, OnabotulinumtoxinA Combination to Clinical Practice: Andrew Blumenfeld, MD
June 08, 2021
The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.
Advantages of Migraine Buddy App: Richard B. Lipton, MD
June 08, 2021
The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.
Ubrogepant Demonstrates Safety, Efficacy in Treating Perimenstrual Migraine
June 08, 2021
Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.
Higher Dose OnabotulinumtoxinA Safe for Chronic Migraine in Real-World Study
June 07, 2021
These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.
STOP 301 Study of INP104 for Migraine: Carrie Dougherty, MD, FAHS
June 07, 2021
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.
External Trigeminal Nerve Stimulation Proves Safety, Efficacy in Migraine Treatment
June 07, 2021
Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.
Collecting Drug-Drug Interaction Data on Rimegepant: Elyse Stock, MD
June 07, 2021
The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.
Early Response to Eptinezumab Predicts Continued Response in Chronic Migraine
June 06, 2021
An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.